Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Releases

News Releases

The information set forth in each press release posted on this page was factually accurate on the date it was issued. While these press releases remain on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of the press releases should not rely upon the information as current or accurate after their issuance dates.

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories Announces Second-Quarter 2020 Results
– Second-Quarter Revenue of $682.6 Million – – Second-Quarter GAAP Earnings per Share of $1.34   and Non-GAAP Earnings per Share of $1.58 – – Increases 2020 Guidance – – Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug.
View HTML
Toggle Summary Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Jul. 14, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday,
View HTML
Toggle Summary HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies LOS ANGELES --(BUSINESS WIRE)--Jun. 2, 2020-- HemaCare Corporation , a Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River Laboratories to Participate in Jefferies and William Blair Conferences
WILMINGTON, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd , at 10:00 a.m. ET , and at the William Blair 40 th Annual Growth Stock
View HTML
Toggle Summary Charles River Laboratories Announces First-Quarter 2020 Results
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 – – Revises 2020 Guidance Due to COVID-19 Impact – WILMINGTON, Mass. --(BUSINESS WIRE)--May 7, 2020-- Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7 th ,
View HTML
Toggle Summary Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)--Mar. 30, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex , a leader in preclinical digital pathology software-as-a-service.
View HTML
Toggle Summary Charles River Laboratories To Participate In Barclays Global Healthcare Conference
WILMINGTON, Mass. --(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference . The Company will present on Wednesday, March 11 th , at 10:15 a.m. ET .
View HTML
Toggle Summary Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
WILMINGTON, Mass. --(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews , M.D., Ph.D., to its Board of Directors, effective February 28, 2020 . Dr. Andrews is Duke University’s Dean Emerita of its School of Medicine, Vice
View HTML
Toggle Summary Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
– Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 – – Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 – – Provides 2020 Guidance –
View HTML
Toggle Summary Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 21, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11 th , before the market opens.
View HTML
Toggle Summary Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment
Together, Charles River and Fios Genomics aim to accelerate preclinical discovery and development by turning complex data into actionable information WILMINGTON, Mass. & EDINBURGH, Scotland --(BUSINESS WIRE)--Jan. 16, 2020-- Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
The integrated drug discovery collaboration will focus on Takeda’s four core therapeutic areas WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 13, 2020-- Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”).
View HTML
Toggle Summary Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 13, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, California , on Tuesday, January 14 th , at 9:30 a.m. PST ( 12:30 p.m.
View HTML
Toggle Summary Charles River Laboratories Completes the Acquisition of HemaCare Corporation
WILMINGTON, Mass. --(BUSINESS WIRE)--Jan. 3, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share.
View HTML

Featured Report

2019 Annual Report (PDF)